President of Q BioMed Inc. Expands on Corporate Update in Q&A
Denis Corin Discusses Mannin Research Inc’s Leading Glaucoma Drug
Candidate MAN-01
March 21 , 2016 Point Roberts WA - Investorideas.com, a digital global news
source covering leading sectors including medical technology and biotech stocks
releases a recent interview with Mr. Denis Corin, President of Q BioMed Inc.
(OTCQB:QBIO). Denis expands on the
recent corporate update and Scrip Intelligence Video released in late February.
He also comments on recent developments with Mannin Research Inc’s leading
glaucoma drug candidate MAN-01. (In October 2015 Q BioMed Inc. entered into an agreement with Mannin
Research to exclusively license, with an option to acquire, the platform
technology assets of Mannin Research, the developer of a new class of vascular
therapeutics.)
Q&A
Q: Investorideas.com
Q: Investorideas.com
Denis, your company’s strategy is to acquire
companies and biomedical assets. Can you expand on that and also share what
assets have been acquired or licensed to date?
A: Mr. Denis Corin, President of Q BioMed Inc.
Sure, our mission is to license and acquire
innovative life sciences assets from academia or small private companies and
provide the strategic resources including financial capital, intellectual
capital, business development and scientific advice to accelerate their product
development timelines to commercialize their drug candidates or bring them to
the next level in terms of valuation inflection.
We have identified several targets that we
believe could provide a substantial pipeline of innovative and high value
assets. We will aim to maximize risk-adjusted returns by focusing on multiple
assets throughout the discovery and development cycle, so we’ll have assets in
pre-clinical, clinical and commercial stages. This allows a nice flow of
development news and value drivers as they all move through their paces. We
expect to benefit from early positioning in illiquid
and/or unknown private assets with multiple potential products in their development
cycle and to capitalize on valuation growth as they move forward in their
development. We believe this gives investors a unique opportunity to
participate in the growth and development of these assets and the value they
bring to the overall pipeline.
In the last quarter of 2015, we entered into an
exclusive License and Purchase Option Agreement with Mannin Research Inc.
whereby we were granted a worldwide, exclusive license, with the option to
acquire their platform assets for Glaucoma and other indications. The Mannin IP
and technology platform is initially focused on developing a first-in-class eye
drop treatment for glaucoma. The technology platform may be expanded in scope
beyond Glaucoma as well as beyond ophthalmological uses and may include cystic
kidney disease and others.
This is an area of therapy that urgently needs a
new offering. No new drugs in this particular indication have been successfully
brought to this market for over 20 years.
The global market for Glaucoma therapeutics is one
of the largest segments of the $23 billion global ophthalmology market. There are 60 million people worldwide
suffering from Glaucoma. It is projected
that the total population suffering from Glaucoma will grow to 80 million by
2020 (W.H.O 2010), so there is an acute need for this type of drug in a very
lucrative market. Our lead candidate, MAN-01, will address this market as a
first-in-class drug that treats abnormal vessels within the eye, thereby
treating Glaucoma at its root causes.
There is no cure for Glaucoma and new
therapeutics are highly sought after. Current therapies and surgical procedures
are not optimally effective, are painful and not well tolerated by patients.
Together with Mannin, we are developing a unique
molecule in the form of an easy-to-administer eye drop, designed to repair the
normal flow of fluid in the eye and resulting in the reduction of intraocular
pressure (IOP), one of the main causes of Glaucoma. Our platform is both unique
and first-in-class and we are the only drug company targeting this method of
action.
IOP caused by abnormal flow of clear fluid
within the eye damages the nerves in the eye, eventually leading to blindness.
A specialized blood vessel, the ‘Schlemm’s Canal’ is the major drainage pathway
for fluid to escape from the front of the eye. Glaucoma can occur when this
canal is either blocked or from a birth defect, resulting in a small or absent
Schlemm’s Canal. Our drug candidate would target the organization of the
Schlemms Canal on a cellular level, thereby creating the optimal environment
for ‘repair’ and improved flow and ultimately, lower IOP.
Given the large 23 Billion dollar ophthalmology market
and the acute need for these types of drugs, we believe there is a substantial
opportunity here. In addition, a deep pipeline of novel therapeutics can be
developed from this research platform, developed and lead by Dr. Quaggin, which
would treat a spectrum of vascular diseases including Cystic Kidney disease.
So to sum up, while this is an earlier stage pre-clinical
asset, we see tremendous opportunity here and look forward to building value in
it as we advance.
Q: Investorideas.com
Can you tell us about your recent addition to
management, Mr. David Laskow-Pooley, as VP Scientific & Product
Development, and the value added to your team in seeking new products for your
pipeline?
A: Mr. Denis Corin, President of Q BioMed Inc.
David is an industry veteran with a very
broad-based and deep knowledge. We are very pleased to have him on board with
us. He has 30 years of experience in all aspects of the discovery, development
and commercialization of pharmaceutical products, diagnostics and devices. He
has a distinguished career working for numerous pharmaceutical and life
sciences companies. David has held director, executive officer and general
management posts in both small and major multinational companies including GSK,
Abbott, Amersham plc, Life Technologies, OSI, Bilcare and Surface Therapeutics.
David brings tremendous operational value to us
as we look at commercializing assets and advancing them through the development
life cycle. He has some very deep and unique experiences that will fit
perfectly with some of the assets we are currently evaluating.
Q: Investorideas.com
Can you talk about Mannin Research Inc’s Glaucoma
treatment technology and its lead drug candidate MAN-01 and the progress it is
making?
A: Mr. Denis Corin, President of Q BioMed Inc
Mannin Research’s (Mannin) Glaucoma therapeutic
is a first-in-class therapeutic designed to treat Primary Open-Angle Glaucoma.
It is based on the research by Dr. Susan Quaggin, Director of the Feinberg
Cardiovascular Research Institute and Chief of the Division of Nephrology and
Hypertension at Northwestern University. The MAN-01 therapeutic is an important
molecule in the context of new pharmaceuticals that can treat Glaucoma.
Mannin’s therapeutic will address increased intraocular pressure in the eye by
acting on a vessel in the eye called the Schlemm’s Canal, which is a main
drainage path for the eye. Mannin is currently in the pre-clinical phase. Optimizing
the molecule, we aim to use it in the clinic in late 2017/early 2018. There we
are looking at demonstrating the effectiveness of this therapeutic in lowering
intraocular pressure (IOP). We are making good progress and are on track to
meet our internal milestones.
Q: Investorideas.com
Aerie Pharmaceuticals, Inc. (Nasdaq: AERI)
reported safety results recently from a trial testing its Glaucoma treatment.
Can you give us a quick differentiation in technology and approach between
Mannin’s MAN-01 and Aerie Pharmaceuticals treatment?
A: Mr. Denis Corin, President of Q BioMed Inc.
Aerie’s approach to treatment in Glaucoma, like ours, is to reduce IOP,
which is the gold standard in measuring the effectiveness of Glaucoma’s
therapeutics. Aerie’s mechanism of action (MOA) is the Rock/NET pathway which
acts primarily on the Tubercular Meshwork, best described as a ‘sieve’ that
sits on top of the main drainage canal in the eye, the ‘Schlemms Canal’. If
this ‘sieve’ becomes inelastic or degraded it inhibits the optimal flow of
fluids to the drain. Imagine, if you will, a ‘leaf-guard’ on top of a gutter on
the roof of your house.
Mannin’s approach is to reduce IOP by addressing
the defective cellular makeup of the actual ‘drain or gutter’ responsible for
70-90% of the fluid movement. Just a small improvement in the performance of
this important vessel can have a significant effect on fluid movement and
reducing IOP. So we believe this is a very important area for therapeutic
development which is currently not being addressed with existing or new
therapeutics in the pipeline.
The technical description of this is described in
Dr. Quaggin’s research published in the JCI 2014 paper (Thompson et all, JCI,
2014).
Q: Investorideas.com
In your recent update you stated it is your goal
to have at least 3 asset transactions completed this year to expand and broaden
your pipeline. Can you tell us what areas within your sector seem promising and
what you are looking into?
A: Mr. Denis Corin, President of Q BioMed Inc.
We are not really looking in any area
specifically. We are just hunting for good value in undervalued or undiscovered
assets that we believe have great potential. That said, we have a few targets
on our due diligence list now that we really like. The most likely to make the
top of that short list is a revenue ready asset that we think could be a
revenue generator in the first year and also has some very exciting indication
expansion possibilities. We’d like to have one deal done in the next quarter
and possibly one more by the end of the year.
We hope interested shareholders and potential
shareholders will stay up to date on our progress and come along for the ride
by visiting our website and sign up for out news updates.
About Q BioMed Inc. ( OTCQB:QBIO)
Q BioMed Inc. ("Q") is a biomedical
acceleration and development company. We are focused on acquiring companies and
biomedical assets. Q is dedicated to providing these target companies and
assets, strategic resources, developmental support, and expansion capital to
ensure they meet their developmental potential enabling them to provide
products to patients in need.
About Investorideas.com
- Big Ideas for Global Investors
InvestorIdeas.com - digital media global news source, PR and social
media in leading sectors.
Sign up for free news alerts at Investorideas.com
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third
party sourced news, articles and equity research as well as creates original
content, including video, interviews and articles. Original content created by
investorideas is protected by copyright laws other than syndication rights. Our
site does not make recommendations for purchases or sale of stocks, services or
products. Nothing on our sites should be construed as an offer or solicitation
to buy or sell products or securities. All investment involves risk and
possible loss of investment. This site is currently compensated for news
publication and distribution, social media and marketing, content creation and
more. Contact each company directly regarding content and press release
questions. Disclosure is posted for each compensated news release, content
published /created if required but otherwise the news was not compensated for
and was published for the sole interest of our readers and followers. More
disclaimer info: http://www.investorideas.com/About/Disclaimer.asp.
Disclosure:
QBIO has retained investorideas.com for PR, media, news publication and social
media effective February 5th for three months: two thousand five hundred per
month.
Additional info regarding BC Residents and global Investors: Effective
September 15 2008 - all BC investors should review all OTC and Pink sheet
listed companies for adherence in new disclosure filings and filing appropriate
documents with Sedar. Read for more info:
http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to
regulations of each country.
Contact
Investorideas.com
800 665 0411
